EVCA, GNVC, CRWEWallstreet.com Stock Report on Friday!

Aug. 6, 2010 - PRLog -- EVCARCO, Inc. (EVCA.OB) recently announced that the company has officially been granted its four Registered Trademarks including “EVCARCO” and its slogan “Future Driven.”

EVCA has received significant attention over the last few months with media and press about its range of electric vehicles, business model and its alliances with the Federal Government. The growth of EVCA has also created a strong value in their name and brand and they have the issuance of these Trademarks by the United States Patent and Trademark office. This issuance further protects and broadens their intellectual property assets as they expand into other regions and markets per their active business model. This gives insight to their dedication, which EVCA so proudly brings to the franchisees and the development of the EVCARCO franchise system.

EVCA plans to introduce the following elements to South America:

1. Government alternative energy advisory
2. Public and commercial electric vehicles
3. Mass transit alternative fuel units
4. All electric taxi and high use units
5. Other viable electric vehicle transportation

EVCA is bringing to market the most advanced clean technologies available in plug-in electric and alternative fuel vehicles.

EVCA has developed a dealer network allowing growth into most US States by 2012.

EVCA has worked diligently to secure their intellectual properties and is proud to has been granted the registration from the U.S. Patent Office. I’m very grateful to have worked alongside all our attorneys at Mullins Law, which took the lead in assisting us to secure these registrations,” stated Scott O’Neal, COO of EVCARCO.

Finally, EVCA has key executives creating alliances with South American governments for long range programs aimed at fossil fuel reduction and adoption of electric vehicles.

More about EVCA at: www.evcarco.com



GenVec Inc. (NasdaqGM: GNVC) said Friday it could receive up to $13 million over four years through a new agreement with Novartis to make clinical trial materials for hearing loss and balance disorder treatment candidates.

In January the Gaithersburg, Md., biotechnology company said it was licensing worldwide rights to its preclinical hearing loss and balance disorders program to Novartis for $5 million upfront and a $2 million stock purchase.

The program is still in the laboratory stage of development.

GenVec said at the time it would also receive funding from the Swiss drugmaker for a research program focused on hearing loss. It is eligible for up to $213.6 million in other payments, based on research and sales milestones.


Sign Up For Free Stock Alerts At http://crwewallstreet.com/signup

********************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEWallStreet publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEWallStreet.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.read more Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received fifteen thousand dollars in cash and thirty-five thousand dollars in EVCARCO, Inc. (EVCA.OB) restricted shares for 30 days of advertising.